You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Intelligent Control For Autonomous Remote Spacecraft

    SBC: ACCURATE AUTOMATION CORPORATION            Topic: N/A

    In Phase I we developed, integrated, and demonstrated a real-time adaptive navigation system, and a companion real-time adaptive guidance system for UAVs. The underlying project goal is to provide an aircraft with the capability to autonomously reroute itself in real time through dynamic hazard environments and still achieve its mission objectives. The adaptive naviagtion system uses an evolutiona ...

    STTR Phase I 2002 National Aeronautics and Space Administration
  2. Intelligent Control For Autonomous Remote Spacecraft

    SBC: ACCURATE AUTOMATION CORPORATION            Topic: N/A

    In Phase I we developed, integrated, and demonstrated a real-time adaptive navigation system, and a companion real-time adaptive guidance system for UAVs. The underlying project goal is to provide an aircraft with the capability to autonomously reroute itself in real time through dynamic hazard environments and still achieve its mission objectives. The adaptive naviagtion system uses an evolutiona ...

    STTR Phase II 2002 National Aeronautics and Space Administration
  3. DEVELOPMENT OF A NEW TREATMENT OF URINARY STONE DISEASE

    SBC: BIOSTRATUM, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Development of a new method for prophylaxis and treatment of urinary stone disease is proposed. Since a majority of urinary stones are made of calcium oxalate, the level of urinary oxalate is one of the major risk factors of stone formation. Unfortunately, there is no effective pharmacological treatment of stone disease that targets urinary oxalate concentratio ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  4. ANAEROBIC MOBILIZATION TECHNOLOGY FOR SOIL REMEDIATION

    SBC: CHATHAM RESEARCH, LTD            Topic: N/A

    DESCRIPTION (provided by applicant): A major contamination issue at over 8,000 sites in the United States are PAHs. This contamination results from almost all combustion processes, creosote treatment of wood, former town gas sites, and many others. Many of these chemicals are both toxic and carcinogenic. It has been observed that these highly hydrophobic chemicals bind tightly to soil by a numb ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  5. A NOVEL DRUG FOR ASTHMA WITH DUAL ACTION VIA AL ARS

    SBC: ENDACEA, INC            Topic: N/A

    The incidence of asthma has more thandoubled from 6.7 million in 1980 to 17.3 million in 1998 in the U.S., including 4.3 million children. Current therapies for asthma have serious side effects. Airway adenosine levels are increased in patients with asthma. Activation of A1 adenosine receptors produces bronchoconstriction, airway edema, and acute inflammation, leading to airflow obstruction. Endac ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  6. P20, MOLECULAR SHORTSTOP FOR INFLAMMATORY LUNG DISEASES

    SBC: Generx+, Inc.            Topic: N/A

    The transcription factor CAAT enhancer binding protein beta (C/EBPbeta) is a key factor orchestrating the inflammatory response. Specifically, expression of the genes encoding the pro-inflammatory cytokines IL-6 and on IL-8 are regulated by C/EBPbeta. C/EBPbeta can be either an activator or an inhibitor of inflammation depending on the dominant isoforms produced. Our data indicate that airway epit ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  7. P20, MOLECULAR SHORTSTOP FOR INFLAMMATORY LUNG DISEASES

    SBC: Generx+, Inc.            Topic: N/A

    The transcription factor CAAT enhancer binding protein beta (C/EBPbeta) is a key factor orchestrating the inflammatory response. Specifically, expression of the genes encoding the pro-inflammatory cytokines IL-6 and on IL-8 are regulated by C/EBPbeta. C/EBPbeta can be either an activator or an inhibitor of inflammation depending on the dominant isoforms produced. Our data indicate that airway epit ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  8. TUBERCLE BACILLI BINDING TO HOST CELLS: VACCINE DESIGN

    SBC: LIGOCYTE PHARMACEUTICALS, INC.            Topic: N/A

    Three million people die each year from tuberculosis (TB) in spite of the use of the existing anti-mycobacterial antibiotics and the BCG vaccine. Clearly, a better vaccine and better ways to treat TB are needed. The purpose of this STTR Phase I feasibility study is to evaluate Mycobacterium tuberculosis-binding interactions with several human cell types and pathogen recognition molecules. Pathogen ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  9. BIONIC BAROREFLEX SYSTEM FOR BLOOD PRESSURE CONTROL

    SBC: TK TX COMPANY            Topic: N/A

    Patients with multiple system atrophy (MSA), a sporadic and progressive neurodegenerative disorder, suffer from orthostatic hypotension, postprandial hypotension and supine hypertension. Hypotension causes presyncopal symptoms usually within seconds of standing and requires the patient to sit or lie down to prevent syncope. Supine hypertension reduces leep quality through excessive nocturnal diur ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  10. AUCONTRAER:VENTILATOR COMPATIBLE AEROSOL DELIVERY DEVICE

    SBC: TK TX COMPANY            Topic: N/A

    Delivery of drugs to the lungs by aerosol (either via a metered dose inhaler, MDI, or nebulization of a solution) is fundamental therapy for a host of lung diseases. Aerosol administration to mechanically ventilated patients is most commonly done by a nurse or respiratory therapist. This approach can be highly variable, is prone to errors particularly in patients on multiple MDIs and nebulizers, h ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government